drugset / Trial / NCT01390064

Vaccination of High Risk Breast Cancer Patients

NCT01390064

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.

Timeline

Start
2011-07
Primary completion
2018-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mimotope P10s-PADRE Vaccine 100 ug Subcutaneous
Subject Mimotope P10s-PADRE Vaccine 300 ug Subcutaneous
Subject Mimotope P10s-PADRE Vaccine 500 ug Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified Subcutaneous

Indications